Idarucizumab adását kö veto en elvégzett szisztémás thrombolysis akut ischaemiás stroke-ban

Translated title of the contribution: Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke

Maté Pásztor, D. Bereczki, Zoltán Szakács, Zsolt May

Research output: Contribution to journalArticle

Abstract

Introduction: Expanding indications have resulted in an increasing number of patients taking novel oral anticoagulants, posing a major treatment dilemma in acute ischemic stroke. Case presentation: We present a successful intravenous thrombolysis in a dabigatran-treated patient with acute ischemic stroke after the administration of idarucizumab. Discussion: According to current guidelines, systemic thrombolysis is contraindicated under treatment with novel oral anticoagulants (taken within 48 hours). In this scenario, idarucizumab offers a solution by reversing the anticoagulant effect of dabigatran. Conclusion: Although there have only been case reports published so far, the dabigatran-antidote idarucizumab seems to give new therapeutic opportunities in the treatment of acute ischemic stroke.

Translated title of the contributionSystemic thrombolysis after the administration of idarucizumab in acute ischemic stroke
Original languageHungarian
Pages (from-to)284-288
Number of pages5
JournalIdeggyogyaszati Szemle
Volume70
Issue number7-8
DOIs
Publication statusPublished - Jul 30 2017

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke'. Together they form a unique fingerprint.

  • Cite this